80岁以上食管癌患者根治性放化疗的临床结局
本研究回顾性分析56例≥80岁食管癌患者接受根治性放化疗(CCRT)的结局,并按1:2倾向评分匹配至65-79岁(n=112)和<65岁(n=112)两个较年轻队列。结果显示三组总生存、无复发生存及中位生存期无显著差异,但高龄组≥3级放射性肺炎发生率显著更高(11% vs 4% vs 0%,P=.003)。
要点
- ≥80岁食管癌患者根治性放化疗的长期疗效与较年轻预后相似人群相当。
- 高龄组≥3级放射性肺炎发生率显著高于较年轻组(11% vs 4% vs 0%,P=.003)。
- 非肺部严重不良事件发生率三组间无显著差异(P=.644)。
核心结论
- ≥80岁食管癌患者接受根治性CCRT后长期临床疗效与预后状态相似的较年轻患者相当。
- 高龄组严重放射性肺炎(≥3级)发生率显著增加,但非肺部严重不良事件无差异。
研究设计与样本
- 单中心回顾性研究,2001-2016年连续56例≥80岁食管癌患者接受常规CCRT,按1:2倾向评分匹配生成65-79岁(n=112)和<65岁(n=112)两个未手术CCRT队列。
- 毒性采用不良事件通用术语标准4.0版评估,生存率用Kaplan-Meier法计算。
主要发现
- 三组中位年龄分别为81岁(80-92)、71岁(65-79)和58岁(20-64),高龄组更常合并心脏疾病。
- 临床完全缓解率三组分别为78%、72%和56%(P=.004)。
- 无复发生存、2年及5年总生存及中位生存期(15.5、23.6、20.2个月,P=.468)三组间无统计学显著差异。
- 总体严重毒性发生率分别为38%、32%和30%(P=.644),放射性肺炎发生率组间可比(P>.05)。
- ≥3级严重放射性肺炎发生率分别为11%、4%和0%(P=.003)。
关键数值与推荐
- 临床完全缓解率:高龄组78%、中间组72%、年轻组56%(P=.004)。
- 中位生存期:高龄组15.5个月、中间组23.6个月、年轻组20.2个月(P=.468)。
- 总体严重毒性率:38%、32%、30%(P=.644)。
- ≥3级放射性肺炎:11%、4%、0%(P=.003)。
临床怎么用
- 对≥80岁食管癌患者,根治性CCRT可作为与较年轻预后相似人群疗效相当的候选方案。
- 高龄患者治疗中需重点关注并防控严重放射性肺炎风险。
- 了解CCRT后肺毒性的预后危险因素可能有助于改善高龄人群的长期结局。
局限性
- 单中心回顾性研究,样本量有限(高龄组56例)。
- 采用倾向评分匹配但可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal treatment approach for patients ≥80 years ("elderly") with esophageal cancer is not well established. We assessed the clinical outcomes in elderly patients treated with definitive chemoradiation therapy (CCRT) at our institution. METHODS AND MATERIALS: 56 consecutive patients ≥80 years with esophageal cancer treated with conventional CCRT between 2001 and 2016 were propensity score matched 1:2 to generate 2 younger patient cohorts treated with CCRT without surgery: "intermediate" (65-79 years, n=112) and "younger" (<65 years, n=112). Treatment related toxicity was assessed using the Common Terminology Criteria for Adverse Events version 4.0. The rates of overall survival (OS) and recurrence-free survival (RFS) were calculated with the Kaplan-Meier method. RESULTS: The median ages of the 3 cohorts were 81 years (elderly, 80-92 years), 71 years (intermediate, 65-79 years), and 58 years (younger, 20-64 years). The elderly cohort was more likely to have cardiac comorbidities. Although the clinical complete response (cCR) rate deviated significantly among the 3 cohorts, (78%, 72%, and 56%; P=.004), the data failed to identify statistically significant differences among RFS, 2-year, and 5-year OS, or in median survival, which was 15.5 months, 23.6 months, and 20.2 months (P=.468), respectively. The overall severe toxicity rates were 38%, 32%, and 30%, respectively (P=.644), including comparable rate of radiation pneumonitis (P>.05). The elderly cohort, however, did show statistically significant evidence of an increased rate of severe radiation pneumonitis (grade ≥3) which was observed to be 11% versus 4% and 0%, respectively (P=.003). CONCLUSIONS: The studied elderly population showed evidence of similar long-term clinical efficacy after definitive CCRT when compared with cohorts of younger patients with similar prognostic status. An increased rate of pulmonary toxicity was identified, without evidence of differences for nonpulmonary severe adverse events. Understanding the prognostic risk factors of pulmonary toxicity after CCRT may effectuate improved long-term outcomes for elderly population.
引用
- Xu C, Xi M, Moreno A, et al. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. Int J Radiat Oncol Biol Phys. 2017. PMID: 28602412. doi:10.1016/j.ijrobp.2017.02.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。